CurrentPremera BluecrossPolicy N/A

15.01.001 Allergen Testing

Defines reimbursement policy for in-vitro specific IgE and total IgE testing, skin and patch testing guidance, non-reimbursable/experimental tests (ALCAT, BAT, IgG/IgA/IgM/IgD, bead-based epitope assays, qualitative multi-allergen screens), and coding references for allergen testing procedures and proprietary assays mentioned.

Policy Summary

PayerPremera Bluecross

Policy15.01.001 Allergen Testing

Policy CodePolicy N/A

Change TypeAdded coverage criteriacoding update

Effective DateFeb 6, 2026

Next Review DateN/A

Key ActionDocument an allergy-focused history and select up to 20 specific IgE tests per year based on clinical indication and use corrected CPT 82787 for billing.

SourceLink

POLICY UPDATE CHANGES

New policy approved October 14, 2025 and published 11/01/25 with effective date for dates of service on or after 2026-02-06.

02/06/26 coding update removed CPT code 83516 and corrected CPT code 82727 to 82787.

up to 20Allowed allergen-specific antibodies per year

6Explicit non-reimbursable tests listed

~50MAmericans affected by allergies (background stat)

1Coding updates recorded

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

1Policy creation event

Coverage Summary

This policy defines reimbursement and testing guidance for allergen evaluation, including in‑vitro specific IgE (sIgE) and total IgE testing, skin and patch testing recommendations, and explicit non‑reimbursable or experimental assays. The policy scope covers targeted sIgE testing limited to allergens selected from the individual's history, exam, and environment with an annual limit of up to 20 allergen‑specific antibodies per year. The coverage stance is mixed: certain sIgE and total IgE testing are reimbursable when criteria are met while several tests (e.g., ALCAT, BAT, bead‑based epitope assays, IgG/IgA/IgM/IgD testing, and qualitative multi‑allergen screens) are not reimbursable. The policy was approved 10/14/2025, published 11/01/2025, and is effective for dates of service on or after 2026-02-06.

Key policy facts

Specific IgE test annual limitUp to 20 allergen-specific antibodies per year

Explicit non-reimbursable tests (count)6 tests listed (ALCAT, BAT, IgG/IgA/IgM/IgD testing, bead-based epitope assays e.g., VeriMAP, qualitative multi-allergen sIgE screen)

Policy creation eventNew policy approved Oct 14, 2025; published 11/01/25

Effective date for coverageDates of service on or after 2026-02-06

Coding update event02/06/26 coding update removed CPT 83516 and corrected CPT 82727 to 82787

Medical-Necessity Criteria

Reimbursable Allergen Testing Indications

Covered when the following criteria logic is satisfied:

ALL of the following

Reimbursable Allergen Testing Indications
- Specific IgE in‑vitro allergy testing targeted to allergens selected based on the individual's history, physical examination, and environment (limit: up to 20 allergen‑specific antibodies per year).
  Limit: up to 20 allergen specific antibodies per year.
- ANY of the following
  - Individual with moderate to severe asthma.
  - Individual with signs or symptoms suggestive of allergic bronchopulmonary aspergillosis (ABPA).

Guidelines, Evidence, and Diagnostic Considerations

Skin testing (SPT) is the preferred, rapid, sensitive, and cost‑effective method to detect IgE‑mediated disease and is recommended when feasible; serum sIgE testing is useful and reimbursable when skin testing is not appropriate or safe (for example, extensive dermatitis, dermatographism, ongoing antihistamines, or when SPT is not available).

The policy summarizes analytic considerations and limitations: skin prick results can vary with operator, device, extract concentration, and measurement technique; serum sIgE assays have high analytical performance when consensus procedures are followed but lack an absolute gold standard for allergic disease diagnosis, so results must be interpreted in clinical context.

Basophil activation testing (BAT) and other cellular activation assays have promising data—particularly for peanut allergy and situations with equivocal SPT/sIgE—but currently lack broad standardization and are considered research/limited clinical utility in many settings; BAT may be useful in specialized labs or select cases but is listed as non‑reimbursable by this policy.

The Antigen Leukocyte Antibody Test (ALCAT) and many broad IgG/IgA/IgM/IgD panels are not reproducible or clinically validated and are not reimbursable. Proprietary bead‑based epitope assays (e.g., VeriMAP Peanut Dx/VeriMAP Peanut Sensitivity) have manufacturer‑claimed high PPV and select published accuracy for peanut BBEA, but the policy considers these emerging/experimental and not reimbursable pending further independent validation.

Component testing (for example, Ara h 2) can improve diagnostic accuracy for peanut allergy and has superior performance compared with whole‑peanut extract for certain use cases; component‑resolved diagnostics are recognized as useful in selected or specialist settings but should not be used indiscriminately and must be interpreted with clinical history.

JTFPP: Patch testing and ACD recommendations

Coding

Serum immunoglobulin and specific IgE CPT codes referencedCPT

82784	Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each
82785	Gammaglobulin (immunoglobulin); IgE
82787	Gammaglobulin (immunoglobulin); immunoglobulin subclasses (e.g., IgG1, 2, 3, or 4), each
86001	Allergen specific IgG quantitative or semiquantitative, each allergen
86003	Allergen specific IgE; quantitative or semiquantitative, crude allergen extract, each
86005	Allergen specific IgE; qualitative, multiallergen screen (e.g., disk, sponge, card)
86008	Allergen specific IgE; quantitative or semiquantitative, recombinant or purified component, each
88184	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker
88185	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker
0165U	Peanut allergen-specific quantitative assessment of multiple epitopes using ELISA; VeriMAP Peanut Dx (proprietary bead-based epitope assay)

1–10 of 11

1/2

Removed/Corrected CPTCPT

83516	CPT code removed (per history: removed)
82727	Corrected to 82787 (per history)
82787	Corrected code replacing 82727 (per history)

Billing Rule

Coding update required

Providers must update coding to use corrected CPT code 82787. Do not bill CPT 83516 after the 02/06/26 coding update.

Affected codes: 82787, 83516 (removed)
Effective date: 02/06/26

Provider Actions & Billing Rules

Documentation Required

Allergen selection must be clinically indicated

Allergen selection for specific IgE testing (codes 86003, 86008) must be based on the patient’s history, physical exam, and environment. Document the allergy-focused history and physical examination to support the choice of allergens.

Codes: 86003, 86008

Billing Rule

Annual limit on specific IgE tests

Reimbursement for in‑vitro specific IgE testing (codes 86003, 86008) is limited to up to 20 allergen‑specific antibodies per year. Ensure testing stays within this annual limit.

Threshold: up to 20 allergen‑specific antibodies per year
Codes: 86003, 86008

Definitions

Term	Definition
ALCAT	Antigen Leukocyte Antibody Test; measures food/immune reactions via leukocyte stimulation (not reproducible clinically per policy)
BAT	Basophil activation test/flow cytometry; measures basophil activation (considered research/limited standardization)
sIgE	Specific immunoglobulin E
tIgE	Total immunoglobulin E
SPT	Skin prick testing — in vivo method to detect IgE-mediated sensitization.
serum sIgE	Serum specific IgE testing — in vitro measurement of allergen-specific IgE antibodies.
BAT (repeat)	Basophil activation test — in vitro functional assay assessing basophil activation; considered nonstandardized for routine use in many contexts.
LDT	Laboratory-developed test — assays developed and validated in-house by clinical laboratories, regulated under CLIA.

Revision History

2025-10-14policy_approval

New policy approved adding language that specific IgE in vitro allergy testing may be considered reimbursable for outlined indications when criteria are met (to be added to Routine Test Management).

2025-11-01publication

Policy published (new policy approved October 14, 2025) describing reimbursable indications and test limitations.

2026-02-06effective_date

Policy Summary

PayerPremera Bluecross

Policy15.01.001 Allergen Testing

Policy CodePolicy N/A

Change TypeAdded coverage criteriacoding update

Effective DateFeb 6, 2026

Next Review DateN/A

Key ActionDocument an allergy-focused history and select up to 20 specific IgE tests per year based on clinical indication and use corrected CPT 82787 for billing.

SourceLink

On This Page

Annual re‑testing of the same food allergen(s) in children and adolescents to monitor allergy resolution when there was an initial positive food allergen result.

Annual re‑testing for same food allergen(s) in children/adolescents is considered reimbursable.

When testing results (serum specific IgE) will be used to inform clinical management decisions (e.g., avoidance strategies, need for supervised oral food challenge, habilitation of immunotherapy decisions) and are selected based on clinical pretest probability and guideline‑recommended indications.

Aligns with WAO, NIAID, AAP, ARIA/International Consensus and EAACI guidance requiring targeted testing based on history and clinical context.

Not Reimbursable / Contraindicated or Experimental Tests

Not reimbursable / considered experimental or contraindicated when any of the following apply:

ANY of the following

Antigen leukocyte antibody test (ALCAT).
Basophil activation flow cytometry testing (BAT)/basophil activation test when used outside established, guideline‑recommended indications or when results are used in lieu of clinical history and gold‑standard provocation testing.
In‑vitro testing of immunoglobulin classes IgG, IgA, IgM and/or IgD for the diagnosis of allergic disease (including allergen‑specific IgG testing).
Bead‑based epitope assays (e.g., VeriMAP Peanut Dx) / proprietary multi‑epitope bead assays when requested for routine diagnostic use outside research or validated contexts.
Qualitative multi‑allergen screening assays that do not identify specific allergens (e.g., non‑specific multi‑allergen screens) when used for routine diagnosis without targeted follow‑up or supporting clinical history.
Routine re‑testing for the same allergens in the absence of a new clinical presentation or change in symptoms (except annual food re‑testing in children/adolescents as specified above).
Routine repeat testing without new clinical indications is not reimbursable.
Use of multiplex or proprietary assays (including some PAMD@/component‑resolved or multiplex panels) for broad screening without individualized, guideline‑based justification; multiplex testing should follow NICE, EAACI, and NIAID recommendations to restrict panels to clinically indicated targets and avoid indiscriminate screening.
Laboratory‑developed tests (LDTs) and proprietary assays offered without CLIA/FDA‑validated performance data or clear clinical utility; providers should ensure LDTs follow CLIA requirements and be aware of FDA/CLIA guidance on investigational or non‑validated assays.
Tests lacking sufficient peer‑reviewed evidence of diagnostic accuracy or clinical utility per major guideline bodies (WAO, NIAID, AAP, EAACI, NICE, National Academies) are considered experimental / not reimbursable.

Considerations for allergic contact dermatitis (ACD) and patch testing:

Consider ACD in the differential diagnosis of patients with chronic eczematous or noneczematous dermatitis.
Strength: Strong; C Evidence
Patch testing gold standard: In patients suspected of ACD, patch testing is the gold standard to confirm the diagnosis.
Strength: Strong; C Evidence
Review products and environment: Review personal products and home/workplace for sources of contact allergens.
Strength: Moderate; D Evidence
Evaluate irritant and allergic causes: Evaluate patients for both irritant and allergic causes, especially hand dermatitis.
Strength: Strong; C Evidence
Suspect allergic CD: Suspect allergic contact dermatitis in generalized and localized eruptions in contact areas.
Strength: Moderate; C Evidence
Facial/periorbital rash: In facial/periorbital rash, evaluate for ACD from cosmetics (fragrances, preservatives, excipients).
Strength: Moderate; C Evidence
Lip/perioral dermatitis: Evaluate lip dermatitis and perioral dermatitis for irritant and allergic causes.
Strength: Moderate; C Evidence
Oral mucosal conditions: Evaluate chronic oral mucosal inflammatory conditions for disorders other than ACD.
Strength: Moderate; C Evidence

JTFPP: Additional patch testing indications

Scalp and neck dermatitis: Dermatitis involving scalp and neck: consider patch testing for sensitizers in cosmetics, hair products, jewelry.
Strength: Moderate; C Evidence
Hand eczema: All patients with acute or chronic hand eczema suspected of contact dermatitis should undergo patch testing.
Strength: Moderate; C Evidence
Axillary dermatitis: evaluate for ACD to deodorants and textiles; consider systemic contact dermatitis.
Strength: Moderate; C Evidence
Anogenital dermatitis: evaluate for ACD to topical products.
Strength: Moderate; C Evidence

JTFPP: Rhinitis diagnostic recommendations

History and exam: Complete a detailed history and physical exam for rhinitis (Strong recommendation).
Medication review: Review current medications to assess drug-induced rhinitis.
Confirm with SPT or sIgE: Perform aeroallergen SPT or sIgE testing to confirm allergic rhinitis when history is consistent.
Strength: Strong; High certainty
Do not routine food testing: Do not perform food SPT or sIgE routinely in evaluation of allergic rhinitis.
Severity instruments:

Denial Risk

Non-reimbursable tests will be denied

Claims for the following tests may be denied as non‑reimbursable: ALCAT, BAT, IgG/IgA/IgM/IgD testing, bead‑based epitope assays (e.g., VeriMAP), and qualitative multi‑allergen screens that do not identify specific allergens. Use of these tests risks claim denial.

Codes: 0165U, 0178U, 86001, 86005
Named non‑reimbursable tests: ALCAT; BAT (basophil activation testing); IgG/IgA/IgM/IgD allergy testing; VeriMAP (bead‑based epitope assay); qualitative multi‑allergen screens

Documentation Required

Total IgE testing justification

For total IgE testing (code 82785) document clinical indication such as moderate to severe asthma or signs/symptoms of allergic bronchopulmonary aspergillosis (ABPA) to support reimbursement.

Code: 82785
Document: moderate to severe asthma or signs/symptoms of ABPA

Documentation Required

Use allergy-focused history before testing

Perform and document an allergy‑focused clinical history and physical examination before ordering allergy tests. Test results must be interpreted in the context of the documented history and exam.

Documentation Required

Competency and facility requirements for SPT in children

Ensure skin prick testing (SPT) in children is performed by clinicians with appropriate competency and only where facilities to manage anaphylaxis are available. Document provider competency and the availability of anaphylaxis management resources.

Competency requirement for personnel
Facility requirement: ability to manage anaphylaxis

Prior Authorization

Avoid indiscriminate panel testing

Avoid routine use of large, indiscriminate multiplex panels (e.g., ImmunoCAP ISAC) and non‑validated multi‑allergen panels. Such testing may require prior authorization or clinical justification due to limited evidence and potential misinterpretation.

Example: ImmunoCAP ISAC (multiplex panels)
May trigger prior authorization or need clinical justification

Documentation Required

When to prefer serum sIgE

Prefer serum sIgE when SPT cannot be performed—for example with extensive dermatitis, dermatographism, ongoing antihistamine therapy, or when SPT is not available in the practice setting. Document the reason SPT is not feasible.

Situations: extensive dermatitis/dermatographism, antihistamines that cannot be stopped, unavailable SPT

Prior Authorization

Effective date for coverage

Policy effective for dates of service on or after 2026-02-06. Confirm member benefits and any prior authorization requirements per the member’s contract before ordering tests or submitting claims.

Effective date: dates of service on or after 2026-02-06
Action: confirm member benefits/prior authorization per contract

Documentation Required

Consult member benefit booklet

Consult the member benefit booklet or contact member services to determine member‑specific coverage limits and prior authorization requirements, since benefits vary by contract. Document verification of benefits as applicable.

Policy effective for dates of service on or after 2026-02-06 following provider notification; includes the reimbursable specific IgE language added in the October 14, 2025 approval.

2026-02-06coding_updateLatest

Coding update: CPT code 83516 removed and CPT code 82727 corrected to 82787; providers must use corrected code 82787 for applicable immunoglobulin subclass reporting and should not bill CPT 83516.

SCD after systemic exposure: Consider systemic contact dermatitis after systemic exposure to known sensitizer with generalized dermatitis or Baboon syndrome.

Strength: Moderate; C Evidence

Foot/leg dermatitis: Consider testing for rubber chemicals, adhesives, leather components in unexplained chronic lower extremity/foot dermatitis.

Strength: Moderate; C Evidence

Atopic dermatitis coexistence: In atopic dermatitis, evaluate for coexisting ACD when suspected.

Strength: Moderate; C Evidence

Consider validated instruments to determine severity and monitor control (conditional).